Research
Hormonal
The contribution of the GIP receptor-activating component of tirzepatide to its effects is uncertain.
Further research is needed to clarify how GIP receptor activation contributes to the effects of tirzepatide.
StrongQualifiesmedium confidence
but the contribution of the GIP receptor-activating component of tirzepatide to these effects is uncertain.
Why this rating
The abstract discusses the role of GIP receptor activation based on literature.
Source
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg et al. · Diabetes Obesity and Metabolism · 2023
DOI 10.1111/dom.15216
reviewCited 35×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →